Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 685-694

  Benabbou, Nadia ^a   Mirshahi, Pezhman ^a   Cadillon, Mélodie ^a   Soria, Jeannette ^a   Therwath, Amu ^a   Mirshahi, Massoud ^a  

^a INSERM   (France)

Author keywords

ATP binding cassette; Chemoresistance; Hospicells; Insulin like growth factor I; JAK2 STAT3; MEK; Ovarian cancer; PI3 kinase signaling pathway

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; JANUS KINASE 2 INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 5; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE CASSETTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JANUS KINASE 2; OVARIAN NEOPLASMS; PODOPHYLLOTOXIN; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84880614899     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2017     Document Type: Article

References (35)

1. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D and Anderson KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82: 3712-3720, 1993.
2. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA and Anderson KC: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104-1112, 1996.
3. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE and Kienast J: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636, 2000.
4. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI and Anderson KC: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961, 2001.
5. Druckmann R and Rohr UD: IGF-1 in gynaecology and obstetrics: Maturitas 41: S65-S83, 2002.
6. Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, De la Longrais IA, Mayne S, Risch H and Yu H: IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 25: 346-354, 2007.
7. Holly J and Perks C: The role of insulin-like growth factor binding proteins. Neuroendocrinology 83: 154-160, 2006.
8. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B and Edwards BK: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100: 1672-1694, 2008.
9. Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fournié JJ, Marie JP, Pujade-Lauraine E, Favre G, Soria J and Mirshahi M: Oncologic trogocytosis of an original stromal cell induces chemoresistance of ovarian tumours. PLoS One 3: e3894, 2008.
10. Sako A, Kitayama J, Yamaguchi H, Kaisaki S, Suzuki H, Fukatsu K and Fujii S: Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res 115: 113-120, 2003.
11. Wilson AP: Mesothelial cells stimulate the anchorage-independent growth of human ovarian tumour cells. Br J Cancer 59: 876-882, 1989.
12. Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M and Couderc B: Hospicells (ascites-derived stromal cells) promote tumori-genicity and angiogenesis. Int J Cancer 126: 2090-2101, 2010.
13. Lis R, Capdet J, Mirshahi P, Lacroix-Triki M, Dagonnet F, Klein C, Mirshahi M, Fournié JJ, Rafii A and Poupot M: Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells. Int J Oncol 37: 1453-1461, 2010.
14. Martinet L, Poupot R, Mirshahi P, Rafii A, Fournié JJ, Mirshahi M and Poupot M: Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer 126: 2143-2152, 2010.
15. Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I, Bourin P, Mirshahi M, Delord JP, Querleu D and Couderc B: Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett 326: 59-68, 2012.
16. Ducros E, Berthaut A, Mirshahi SS, Faussat AM, Soria J, Agarwal MK and Mirshahi M: Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. Biochem Biophys Res Commun 373: 192-196, 2008.
17. Smith JA, Ngo H, Martin MC and Wolf JK: An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 98: 141-145, 2005.
18. Kucerova L and Skolekova S: Tumor microenvironment and the role of mesenchymal stromal cells. Neoplasma 60: 1-10, 2013.
19. Beauchamp MC, Yasmeen A, Knafo A and Gotlieb WH: Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010: 257058, 2010.
20. Belfiore A and Frasca F: GF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13: 381-406, 2008.
21. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED, Kaaks R and Hayes RB: IGF-I and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 121: 2267-2273, 2007.
22. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y and Pollak MN: Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100: 389-396, 2006.
23. Grivennikov S and Karin M: Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13: 7-9, 2008.
24. Gest C, Mirshahi P, Li H, Pritchard LL, Joimel U, Blot E, Chidiac J, Poletto B, Vannier JP, Varin R, Mirshahi M, Cazin L, Pujade-Lauraine E, Soria J and Soria C: Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets. Cancer Lett 317: 207-217, 2012.
25. Walther W and Stein U: Therapeutic genes for cancer gene therapy. Mol Biotechnol 13: 21-28, 1999.
26. Kang Y and Perry RR: Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 54: 2952-2958, 1994.
27. Stein U, Walther W, Lemm M, Naundorf H and Fichtner I: Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer 72: 885-891, 1997.
28. Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, Yao M, Zheng S and Gu J: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29: 2289-2297, 2008.
29. Fischer B, Frei C, Moura U, Stahel R and Felley-Bosco E: Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function, and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer 78: 23-29, 2012.
30. Zatelli MC, Minoia M, Molè D, Cason V, Tagliati F, Margutti A, Bondanelli M, Ambrosio MR and degli Uberti E: Growth hormone excess promotes breast cancer chemoresistance. J Clin Endocrinol Metab 94: 3931-3938, 2009.
31. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H; AOCS Study Group, Harnett PR, Brown R, DeFazio A and Chenevix-Trench G: ABCB1 (MDR1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 14: 5594-5601, 2008.
32. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
33. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
34. Chen HHW and Kuo MT: Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010: 1-7, 2010.
35. Grothey A, Voigt W, Schöber C, Müller T, Dempke W and Schmoll HJ: The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 125: 166-173, 1999.